

The image is a composite. The top half shows a hospital hallway with a reception desk labeled 'Respiratory Dept'. Two staff members are at the desk, and two doctors in white coats are walking in the background. The bottom right corner shows a bright blue door set in a cream-colored frame, with a white picket fence and purple flowers in the foreground.

Are you **OPEN** to new ways  
of thinking about **secretion management?**

## Open Airways™

### Maintaining airway access to ensure that your options are always open.

The treatment of acute respiratory conditions and chronic respiratory illness involves many therapeutic treatments but always includes one critical goal, keeping airways open. One of the most effective ways to open airways, and to keep them open, is to manage secretions.

Effective secretion management — detection, hydration, mobilization, removal and collection of excessively thick respiratory secretions — helps improve or preserve respiratory health and promotes positive patient outcomes.

Smiths Medical, a leader in respiratory health, is looking at secretion management in a new way. From hospital to home care, our approach is clinically focused. For whatever secretion management challenges you face — lung infections, atelectasis, ventilation, decreased lung volumes — Smiths Medical can help you achieve more successful interventions and enhanced outcomes.

---

In acute care settings, pulmonary therapy is important for patients at risk for atelectasis. A study conducted at the University of Pittsburgh concluded the implementation of a respiratory treatment protocol can decrease ventilator days, ICU stays and lower total hospital costs.<sup>1</sup>

---

acapella®  
Vibratory PEP Therapy System

### Principal interventions for secretion mobilization and removal.

Positive Airway Pressure (PAP) therapy, which also includes Positive Expiratory Pressure (PEP) therapies, is used as part of a broader bronchial hygiene therapy program for the mobilization and removal of secretions, particularly in patients with atelectasis, COPD and cystic fibrosis. It can successfully:

- Reduce air trapping, common with asthma and COPD
- Aid in the mobilization of retained secretions as are found in cystic fibrosis and chronic bronchitis
- Prevent or reverse atelectasis
- Optimize the delivery of bronchodilators

Smiths Medical's specialized products can provide these therapeutic benefits across the continuum of care.



## Effective therapies tailored to specific respiratory needs

	Post-operative/ Atelectasis <sup>2,12-14</sup>	COPD <sup>2,4-9</sup>	Cystic Fibrosis <sup>2-4,10,11</sup>
Vibratory PEP Therapy	■ ■ ■ ■ ■	■ ■ ■ ■ ■	■ ■ ■ ■ ■
PEP Therapy	■ ■ ■ ■ ■	■ ■ ■ ■ ■	■ ■ ■ ■ ■
PAP Therapy (periodic or continuous)	■ ■ ■ ■ ■	■ ■ ■ ■ ■	■ ■ ■ ■ ■
Chest Physiotherapy	■ ■ ■ ■ ■	■ ■ ■ ■ ■	■ ■ ■ ■ ■
Incentive Spirometry	■ ■ ■ ■ ■	■ ■ ■ ■ ■	■ ■ ■ ■ ■

# OPEN AIRWAYS™

## Smiths Medical


Offering secretion management solutions for hospital care, home care and life.

Smiths Medical can help you achieve more successful interventions and enhanced outcomes with:

- A full portfolio of products that target the treatment of chronic and hyper secretions
- Unique, proprietary products for PAP and vibratory PEP therapy
- A compendium of clinical evidence to support the clinical results and outcomes
- Products that are easy to use and register high patient compliance
- Patient educational materials including videos
- Protocol and care pathways developed by clinicians
- Clinical education programs

We're ready to share our new approach with you.

**TheraPEP®**  
Positive Expiratory Pressure  
Therapy System



EzPAP®  
Positive Airway Pressure System

1. Brian G Harbrecht, MD, Edgar Delgado RRT, Rayomnd P Tuttle RRT, Mark H Cohen-Melamed RRT, Melissa I Saul MSc, and Cynthia A Valenta RN MSN CNRN Improved Outcomes with Routine Respiratory Therapist Evaluation of Non-Intensive-Care-Unit surgery Patients. *Respiratory Care*, July 2009 Vol 54 No 7 pages 861-867.
2. AARC Clinical Practice Guideline: Use of PAP Adjuncts to Bronchial Hygiene Therapy, *Respir Care* 38(5):516-521, 1993.
3. McCool D, Rosen M, Nonpharmacologic Airway Clearance Therapies: AACP Evidence Based Clinical Practice Guidelines. *Chest*. 2006;129:250-259.
4. Flume PA, Robinson KA, O'Sullivan BP, et al. Cystic Fibrosis Pulmonary Guidelines; airway clearance therapies. *Respir Care*. Apr 2009; 54(4): 522-537.
5. Naraparaju S, Vaishali K, Venkatesan P, Acharya V. A comparison of the Acapella and a threshold inspiratory muscle trainer for sputum clearance in bronchiectasis-A pilot study. *Physiother Theory Pract*. Aug 2010;26(6):353-357.
6. Christensen EF, Nedergaard T, Dahl R. Long-term treatment of chronic bronchitis with positive expiratory pressure mask and chest physiotherapy. *Chest*. Mar 1990;97(3):645-650.
7. Su CL, Chiang LL, Chiang TY, Yu CT, Kuo HP, Lin HC. Domiciliary positive expiratory pressure improves pulmonary function and exercise capacity in patients with chronic obstructive pulmonary disease. *J Formos Med Assoc*. Mar 2007;106(3):204-211.
8. Holland AE, Button BM. Is there a role for airway clearance techniques in chronic obstructive pulmonary disease? *Chron Respir Dis*. 2006;3(2):83-91.
9. Hill K, Patman S, Brooks D. Effect of airway clearance techniques in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease: a systematic review. *Chron Respir Dis*. 2010;7(1):9-17.
10. van der Schans CP, van der Mark TW, de Vries G, et al. Effect of positive expiratory pressure breathing in patients with cystic fibrosis. *Thorax*. Apr 1991;46(4):252-256.
11. McCarren B, Alison JA. Physiological effects of vibration in subjects with cystic fibrosis. *Eur Respir J*. Jun 2006;27(6):1204-1209.
12. Ricksten SE, Bengtsson A, Soderberg C, Thorden M, Kvist H. Effects of periodic positive airway pressure by mask on postoperative pulmonary function. *Chest*. Jun 1986;89(6):774-781.
13. Elliott S. P68 A study to investigate the clinical use and outcomes of EZPAP positive pressure device. *Thorax*. December 1, 2011 2011;66(Suppl 4):A96.
14. Wiersgalla S. Effects of EzPAP postoperatively in coronary artery bypass graft patients. Paper presented at: 48th International Respiratory Congress for the AARC Annual Convention and Exhibition 2002; Tampa, FL.

PRODUCT(S) DESCRIBED MAY NOT BE LICENSED OR AVAILABLE FOR SALE IN CANADA AND OTHER COUNTRIES.

**Smiths Medical International Ltd.**

Ashford, UK TN25 4BF  
Phone: +44 (0) 845 8500445

Find your local contact information at:  
[www.smiths-medical.com/customer-support](http://www.smiths-medical.com/customer-support)

Smiths Medical is part of the global technology business Smiths Group plc. Portex, acapella, EzPAP, TheraPEP and the Smiths Medical and Portex design marks are trademarks of Smiths Medical. The symbol ® indicates the trademark is registered in the U.S. Patent and Trademark Office and certain other countries. All other names and marks mentioned are the trademarks or service marks of their respective owners. ©2013 Smiths Medical. All rights reserved. RE194297GB-082013



**smiths medical**